SCHEMBL3843300

SCHEMBL3843300

CCOC(=O)Cc1nnnn1Cc1c2cccc(-c3ccc(Cl)cc3Cl)c2nn1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
CRHR1 P34998 7/20 0.37
TSHR P16473 3/20 0.37
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
SLC6A4 P31645 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CNR1 P21554 1/20 0.34
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPK1 P28482 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK8 P45983 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3839291 0.88 CRHR1 (0.37) CRHR1ALDH1A1POLB
SCHEMBL3838866 0.87 CRHR1 (0.37) SMN1; SMN2CRHR1TSHRHTR2AHTR2C
SCHEMBL3839859 0.84 HSD17B10 (0.43) SMN1; SMN2CRHR1TSHRALDH1A1CNR1
SCHEMBL3839759 0.83 CRHR1 (0.39) CRHR1POLB
SCHEMBL3842403 0.81 CRHR1 (0.37) SMN1; SMN2CRHR1TSHRALDH1A1CNR1
SCHEMBL3843615 0.78 CRHR1 (0.40) CRHR1POLB
SCHEMBL3843991 0.77 CRHR1 (0.38) CRHR1ALDH1A1POLBCYP1A2CYP2C9
SCHEMBL3844049 0.77 CRHR1 (0.41) CRHR1ALDH1A1POLB
SCHEMBL14378006 0.76 CRHR1 (0.45) CRHR1MAPT
SCHEMBL3843569 0.76 CRHR1 (0.44) CRHR1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007753-B1 HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-11-11 EP disclosed
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC 2007-10-11 US disclosed
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC 2007-10-11 US disclosed
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators GABRA1, GABRA2, GABRA3 SMN1; SMN2 2930/4885CRHR1 96/4885TSHR 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.